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SEPARATION OF CD4 T CELL-MEDIATED GRAFT-VERSUS-HOST RE-
SPONSES FROM THE GRAFT-VERSUS-LEUKEMIA EFFECT
Lewandowski, A.M.; Friedman, T.M.; Korngold, R. Kimmel Cancer
Center/Thomas Jefferson University, Philadelphia, PA.
Graft-versus-host disease (GVHD) can result from transplanta-
tion of blood and bone marrow cells into major histocompatibility
complex (MHC)-matched recipient mice due to donor T cell
recognition of minor histocompatibility antigens (miHA). Graft-
versus-leukemia (GVL) responses can be directed to distinct or
over expressed leukemia-restricted antigens presented by MHC
class I or class II molecules. In addition, donor T cells which are
responsible for the induction of GVHD may also mount a GVL
effect directed to shared host miHA on tumor cells. We have
previously described CD4 T cell-mediated lethal GVHD in the
B6 anti-BALB.B miHA model and characterized the B6 anti-host
response over the course of disease development, in the absence of
leukemia challenge. Using a BALB.B-derived myeloid leukemia
cell line (MMBALB7), we subsequently investigated the GVL
activity in this GVHD model. We ﬁrst transferred B6 CD4 T
cells, presensitized to the BALB.B leukemia cell line, to bone
marrow-reconstituted syngeneic recipients and observed effective
GVL protection against the leukemia challenge. Then, in order to
better characterize this B6 CD4 T cell anti-leukemia response, T
cell receptor V CDR3-size spectratype analysis was performed.
B6 mice were stimulated with the MMBALB7 leukemia cell line
and the CD4 T cell response from the draining lymph nodes was
analyzed. The B6 anti-leukemia spectratype results were compared
to the previously reported B6 anti-BALB.B GVHD responses.
These results indicate anti-leukemia VTCR usage that was either
unique or overlapping in both the GVHD and GVL responses.
Speciﬁcally, V 1 and 5 families were uniquely involved in the
anti-leukemia response, whereas V 3, 8.2, 8.3, 11, 13, and 14
families were skewed in both the anti-leukemia and anti-BALB.B
GVHD responses. The presence of V families that are likely
recognizing leukemia-restricted antigens in the GVL response
suggests that it is possible to separate these responses from those
responsible for GVHD, allowing for optimum immunotherapeutic
potential.
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ANALYSIS OF GENE EXPRESSION PROFILE IN PATIENTS WITH ACUTE
GRAFT VERSUS HOST DISEASE FOLLOWING HAEMATOPOIETIC STEM
CELL TRANSPLANTATION
Tabellini, L.; Lin, M.-T.; Fan, W.; Pogosova-Agadjanyan, E.; Stephens,
B.; Zhao, L.P.; Radich, J.; Hansen, J.A. Fred Hutchinson Cancer
Research Center, Seattle, WA.
To better understand the cellular events that precede clinical
onset of GVHD we compared gene expression proﬁles in patients
3 weeks after transplantation from normal donor following my-
eloablative conditioning. Blood leucocytes were obtained at sched-
uled times prior to administration of steroids. RNA was biotin
labeled and hybridized on Affymetrix HG U133A chips. In a ﬁrst
set of experiments we compared global gene expression proﬁles
among 15 patients and 10 normal controls. A total of 1176 genes
were differentially expressed between patients and controls. The
expression proﬁles of these 1176 genes was further compared
between 8 patients who developed GVHD within the next 1 to 5
days and 7 patients who remained GVHD free for at least 90 days.
Nine genes were differentially expressed in these two groups
(NFD1): 3 were increased, 6 were decreased in GVHD patients.
In addition to the global comparison, we examined expression for
a candidate list of 189 genes and found 6 genes (NFD1) associ-
ated with onset of GVHD: 4 were increased, 2 were decreased. In
a second set of experiments we compared changes occurring within
7 patients between 3 and 4 weeks post-transplant. Using a pairwise
comparison we found 55 increased genes and 88 decreased among
4 patients developing GVHD within 7 days. Among the increased
genes 3 were associated with adaptive immune response and 5 with
inﬂammation. Among the decreased genes 3 were associated with
cell metabolism, 6 with DNA repair, replication and cell cycle, 5
with signal transduction, 10 with adaptive immune response in-
cluding 4 T cell associated genes. These results demonstrate ex-
tensive changes in gene expression during early post-transplant
period the majority of which are not obviously associated with
immune response. By candidate gene approach we detected a
smaller number of genes associated with onset of GVHD. We
found that the most informative approach was to compare longi-
tudinal changes within the same patient. We observed a paradox-
ical decrease in the expression of genes associated with cell cycle
and T cell function. This may be explained by previous studies
demonstrating activation induced cell death during clinical
GVHD, and the ﬁnding of profound lymphopenia in patients with
GVHD. Further studies will be necessary to determine if gene
expression proﬁling can be useful in identifying a molecular “sig-
nature” for GVHD, and if this approach can be of value in mon-
itoring or predicting response to GVHD treatment.
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DENLEUKIN DIFTITOX (ONTAK) FOR THE TREATMENT OF ADVANCED
STEROID REFRACTORY GRAFT-VERSUS-HOST DISEASE (SR-GVHD): A
SINGLE INSTITUTION EXPERIENCE
Bubalo, J.S.; Maziarz, R.T.; Subbiah, N.; Curtin, P.T.; Simic, A.;
Hayes-Lattin, B.M.; Schubach, S.E.; Jacoby, C.E.; Leis, J.F. Oregon
Health & Science University, Portland, OR
SR-GVHD is a leading cause of morbidity and mortality follow-
ing allogeneic stem cell transplantation. Denileukin diftitox (DD),
a recombinant fusion protein composed of the cytocidal A chain of
diphtheria toxin and binding portion of interleukin-2, has potent
activity against activated CD25T cells important in the etiology
of GVHD. Recent reports suggest that DD may have therapeutic
activity for the treatment of SR-GVHD. SR-GVHD was deﬁned
as lack of response or disease progression after at least 7 days of
treatment with methylprednisolone at 2 mg/kg. Eleven patients
received allogeneic transplant, 2 after MRD and 9 after URD (7
matched, 1 C antigen mismatch, 1 three allele mismatch). GVHD
prophylaxis consisted of cyclosporine (CsA), methotrexate (MTX),
plus steroids (10) or CsA and MTX (1). Seven patients developed
acute SR-GVHD overall grade III (2) or IV (5) while 4 had chronic
extensive SR-GVHD. Five patients had 2 organ (skin and GI)
grade IV GVHD and 6 had 3 organ involvement (skin, GI, and
liver). Six patients had prior admissions for treatment of GVHD
and all patients had failed a median of 2.5 agents (range 1–5) prior
to DD including dacluzimab (4), MMF (6), tacrolimus (7), siroli-
mus (1) and beclomethasone (1). Median day to DD therapy after
stem cell transplant was day 76 (30–311). Planned treatment for
DD was at a dose of 600 mcg (approximately 9 mcg/kg) on days 1,
3, 5, 15, 17 and 19 (Ho, Blood, 2004). Two patients with cGVHD
developed hyperbilirubinemia without elevation of hepatic en-
zymes on DD. Five patients including 3 of 4 with cGVHD died
prior to completing the full course of treatment (1–3 doses). These
patients succumbed to GI bleed secondary to gut GVHD and
CMV colitis (1), fungal pneumonia (2), and ARDS (2). Six patients
received all six doses of DD. All 6 showed response to treatment
with 1 patient with grade III aGVHD achieving a CR and 5
achieving a PR, deﬁned as at least a one overall grade improvement
in GVHD staging. Five of the 6 patients have died with patients
dying of CMV pneumonia (1), multi-organ failure (1), IPS (1),
aspergillus pneumonia (1), and respiratory arrest (1). Steroids could
be tapered in 8 of 10 patients. Median survival for the entire group
was 20 days from the onset of DD treatment (range 5–440 days)
with median survival of 34 days for patients who received all 6
doses of DD. These results demonstrate that patients with ad-
vanced SR-GVHD can respond to DD and suggest that earlier
treatment may improve outcomes.
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MURINE CIK CELLS SHOW TUMOR SPECIFIC CYTOLYSIS IN CD107A
BASED DEGRANULATION ANALYSIS
Baker, J.; Schulz, S.; Beilhack, A.; Eftekhari, K.; Negrin, R.S. Depart-
ment of Medicine, Division of BMT, Stanford University, Stanford, CA.
Immunotherapy with cytokine induced killers cells (CIK) is ef-
fective in the treatment of malignancies in several murine models.
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